Experienced in Gout

Dr. Asad Fraser

Gilbert Barbee Moore And Mcilvoy Psc
Bowling Green, KY
Experienced
in Gout
Specialties:Rheumatology
OverviewInsuranceLocationsClinical Research

Overview

Asad Fraser is a Rheumatologist in Bowling Green, Kentucky. Dr. Fraser and is rated as an Experienced provider by MediFind in the treatment of Gout. His top areas of expertise are Undifferentiated Connective Tissue Disease (UCTD), Psoriasis, Rheumatoid Arthritis (RA), and Psoriatic Arthritis.

His clinical research consists of participating in 5 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Rheumatology
Licenses
Internal Medicine in KY
Languages Spoken
English
Gender
Male

Insurance

Please contact the provider to confirm they accept your insurance or if you don't see your insurance listed.

Accepted insurance plans

  •  Humana

Locations

GILBERT BARBEE MOORE AND MCILVOY PSC
201 Park St, Bowling Green, KY 42101
270-781-5111

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

A Multi-centre Long-term Extension Study to Assess the Safety and Efficacy of GSK3196165 in the Treatment of Rheumatoid Arthritis
A Multi-centre Long-term Extension Study to Assess the Safety and Efficacy of GSK3196165 in the Treatment of Rheumatoid Arthritis
Enrollment Status: Terminated
Publish Date: February 07, 2024
Intervention Type: Drug, Biological
Study Drugs: Otilimab, csDMARD
Study Phase: Phase 3
A 52-week, Phase 3, Multicentre, Randomised, Double Blind, Efficacy and Safety Study, Comparing GSK3196165 With Placebo and With Tofacitinib in Combination With Conventional Synthetic DMARDs, in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Conventional Synthetic DMARDs or Biologic DMARDs
A 52-week, Phase 3, Multicentre, Randomised, Double Blind, Efficacy and Safety Study, Comparing GSK3196165 With Placebo and With Tofacitinib in Combination With Conventional Synthetic DMARDs, in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Conventional Synthetic DMARDs or Biologic DMARDs
Enrollment Status: Terminated
Publish Date: November 30, 2023
Intervention Type: Drug, Biological
Study Drugs: Otilimab, Tofacitinib, csDMARDs
Study Phase: Phase 3
A Multicenter, Open-Label, Phase III Study of the Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis
A Multicenter, Open-Label, Phase III Study of the Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis
Enrollment Status: Completed
Publish Date: October 12, 2023
Intervention Type: Drug
Study Drugs: Olokizumab, Methotrexate
Study Phase: Phase 3
A Randomized, Double-Blind, Parallel-Group, Placebo- and Active-Controlled, Multicenter Phase III Study of the Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis Inadequately Controlled by Methotrexate Therapy
A Randomized, Double-Blind, Parallel-Group, Placebo- and Active-Controlled, Multicenter Phase III Study of the Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis Inadequately Controlled by Methotrexate Therapy
Enrollment Status: Completed
Publish Date: September 21, 2023
Intervention Type: Drug
Study Phase: Phase 3
A Randomized, Double-blind, Parallel-group, Placebo-controlled, Multicenter Phase III Study of the Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis Inadequately Controlled by Tumor Necrosis Factor Alpha (TNF-α) Inhibitor Therapy
A Randomized, Double-blind, Parallel-group, Placebo-controlled, Multicenter Phase III Study of the Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis Inadequately Controlled by Tumor Necrosis Factor Alpha (TNF-α) Inhibitor Therapy
Enrollment Status: Completed
Publish Date: September 21, 2023
Intervention Type: Drug
Study Drug: Olokizumab
Study Phase: Phase 3
View 4 Less Clinical Trials
Similar Doctors
Expertise in
13
conditions
Dr. Daksha P. Mehta
Rheumatology
Expertise in
13
conditions
Dr. Daksha P. Mehta
Rheumatology
584 Westport Rd, Ste 101, 
Elizabethtown, KY 
 (57.2 mi)
270-769-2535
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Daksha Mehta is a Rheumatologist in Elizabethtown, Kentucky. Dr. Mehta and is rated as a Distinguished provider by MediFind in the treatment of Gout. Her top areas of expertise are Rheumatoid Arthritis (RA), Osteoporosis, Postmenopausal Osteoporosis, and Bursitis. Dr. Mehta is currently accepting new patients.

Expertise in
2
conditions
Dr. Scott F. Lewis
Rheumatology
Expertise in
2
conditions
Dr. Scott F. Lewis
Rheumatology

LC Rheumatology & Infusion Center

340 New Towne Drive, 
Bowling Green, KY 
 (2.5 mi)
270-257-4217
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Scott Lewis is a Rheumatologist in Bowling Green, Kentucky. Dr. Lewis and is rated as an Advanced provider by MediFind in the treatment of Gout. His top areas of expertise are Rheumatoid Arthritis (RA), Gout, Bursitis, and Tenosynovitis. Dr. Lewis is currently accepting new patients.

Expertise in
7
conditions
Dr. Neha A. Pansuria
Rheumatology
Expertise in
7
conditions
Dr. Neha A. Pansuria
Rheumatology

Gilbert Barbee Moore And Mcilvoy Psc

201 Park St, 
Bowling Green, KY 
270-781-5111
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Neha Pansuria is a Rheumatologist in Bowling Green, Kentucky. Dr. Pansuria and is rated as an Advanced provider by MediFind in the treatment of Gout. Her top areas of expertise are Rheumatoid Arthritis (RA), Psoriatic Arthritis, Psoriasis, and Undifferentiated Connective Tissue Disease (UCTD). Dr. Pansuria is currently accepting new patients.

Areas of Expertise

When evaluating expertise, MediFind pulls from factors such as the number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

To learn more about how MediFind determines the expertise levels, check out our expert tiers page.

Search for your specific condition
Want to save this doctor for later?
Sign Up
Looking for the best doctor for you?
Start Here
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile